Clinical Trial Update: A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 proof-of-concept study assessed antiviral activity, safety, and pharmacokinetics of the CCR5 antagonist TBR-652 in HIV-1 infected, antiretroviral-ex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TBR-652 (TBR-652)

Snippet

Sponsor: Tobira Therapeutics, Inc. | Conditions: HIV-1 Infection | Phase 1, Phase 2 | Status: COMPLETED